Phase 2a win and fresh $200M gives bempikibart a clear run at registration — but a single-arm, open-label dataset must hold up in a controlled pivotal trial

Bull

Regulators align with Q32 Bio on a clear, achievable trial design for severe/very severe alopecia areata — including an agreed primary endpoint, population definition, and randomized controlled structure — that allows the H1 2027 registration trial initiation to proceed on schedule. A favorable outcome would validate that the SIGNAL-AA Part B dataset is sufficient to anchor a registrational package and would de-risk the pivotal investment against the $200M cash runway, materially compressing the perceived gap between Phase 2a and approval.

Bear

Regulators could require a larger, more complex, or longer-duration controlled trial than the company anticipates, impose a comparator arm against an approved JAK inhibitor, or raise concerns about the single-arm open-label design as a basis for registration — any of which would extend timelines, increase capital requirements, or force protocol redesign. The most likely failure mode is a mismatch between the FDA's evidentiary bar for a controlled pivotal and the signal observed in a 33-patient open-label study, particularly if regulators are skeptical of SALT-based endpoints or durability data from short off-drug follow-up.